![](/img/cover-not-exists.png)
Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial
Berger, Anne Katrin, Lücke, Stephan, Abel, Ulrich, Haag, Georg Martin, Grüllich, Carsten, Stange, Annika, Dietrich, Mareike, Apostolidis, Leonidas, Freitag, Angelika, Trierweiler, Claudia, von Gall, CLanguage:
english
Journal:
British Journal of Cancer
DOI:
10.1038/s41416-018-0152-4
Date:
July, 2018
File:
PDF, 612 KB
english, 2018